

Flexi-Seal™
SIGNAL™
FMS

A LEADING-EDGE SOLUTION FROM THE FLEXI-SEAL™
FAECAL MANAGEMENT SYSTEM

It can hit any hospital.



Contain *C. difficile* before it strikes.



Flexi-Seal™ SIGNAL™ FMS is a
closed system that minimizes exposure
to potentially infectious waste.



C. difficile

Are you aware of the consequences?

Clostridium difficile is a nosocomial infection that can cause diarrhea and life-threatening intestinal conditions such as pseudomembranous colitis, toxic megacolon, sepsis and death.¹ Antibiotic treatment is the most widely recognised risk factor for *C. difficile* infection.²


Dramatic developments worldwide

- Evidence shows significant increases in *C. difficile* incidences in North America and Europe.³
- US: prevalence rate of 13.1 per 1,000 inpatients.¹
- UK: a total of 25,600 cases registered in 2009.⁴
- Germany: total number of incidents estimated to 58,000 cases in 2008.⁵




Impact on the cost of treatment

- Infection-related costs can exceed \$13,675 per case.⁶
- Increases length of stay by 3.6 days per patient.⁷
- Increases nursing time.
- Creates a need for patient isolation.
- Creates a need for increased use of drugs.



The spread of *C. difficile* – the biggest problem of all

- *C. difficile* spores can survive for up to five months in the environment.⁸
- *C. difficile* can be acquired from contact with contaminated surfaces.⁹
- *C. difficile* is transmitted via a faecal-oral route⁹ and through the air.¹⁰



Flexi-Seal™ SIGNAL™ FMS

Scientifically proven to contain *C. difficile*.^{11,12}

Faecal management systems can only play a role in minimising environmental bacterial load if they effectively contain the *C. difficile*-spores.

Effective containment

In-vitro study results demonstrate that Flexi-Seal™ FMS and the unique Flexi-Seal™ Filtered Collection Bags:

- Effectively contain *C. difficile*.
- Minimise the airborne spread of *C. difficile* spores by reducing the need to release excess air from the collection bag.
- Are valuable infection control tools when managing patients with *C. difficile*.

Flexi-Seal™ SIGNAL™
The seal of innovation™

Are you doing all you can
to stop infection from spreading?


Flexi-Seal™ SIGNAL™ FMS is a closed system that minimises the exposure to potentially infectious waste.

Unique charcoal membrane filter provides efficient venting and stops the collection bag from ballooning.



Flexi-Seal™ FMS: The Most Widely Used Faecal Management System¹³

Engineered by a company with a heritage of over 30 years' experience in wound, ostomy, continence and skin care.



To learn more about the benefits of Flexi-Seal™ SIGNAL™ FMS, call:
Australia: **1800 339 412**
New Zealand: **0800 441 763**
www.convatec.com.au

www.convatec.com.au

References: **1.** Jarvis WR, Schlosser JA, Jarvis AA, Chinn RY. National point prevalence study of *Clostridium difficile* in US health care facility inpatients, 2008. The Association for Professionals in Infection Control and Epidemiology, Inc. (APIC). Am J Infect Control 2009;37:263-70 **2.** Blossom DB, Clifford McDonald L. The challenges posed by reemerging *Clostridium difficile* infection. CID, 2007;45:222-7 **3.** Kuijper EJ, Barbut F, Brazier JS, et al. Update of *Clostridium difficile* infection due to PCR ribotype 027 in Europe, 2008. Eurosurveillance, Volume 13, Issues 7-9, Jul-Sep 2008. **4.** Financial year counts & rates of *Clostridium difficile* infection by NHS acute trust (FY 2007/08 - 2009/10), www.hpa.org.uk, accessed on Oct. 14, 2010 **5.** Zaiss NH, Witte W, Nübel U. Fluoro-quinolone Resistance and *Clostridium difficile*, Germany. Robert Koch Institute. Emerging Infectious Diseases, Vol. 16, no. 4, April 2010 **6.** O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of *Clostridium difficile*-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28(11):1219-1227 **7.** Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to *Clostridium difficile*. CID, 2002;34:346-53 **8.** *Clostridium difficile*: a sometimes fatal complication of antibiotic use. PA PSRS Patient Saf Advis 2005 Jun;2(2):1-8. **9.** Guide to the elimination of *Clostridium difficile* in Healthcare settings. Association for Professionals in Infection Control and Epidemiology (APIC) 2008. **10.** Best EL, Fawley WN, Parnell P, Wilcox MH. The potential for airborne dispersal of *Clostridium difficile* from symptomatic patients, CID, 2010;50:1450-57 **11.** Containment of *Clostridium difficile* by the Flexi-Seal® Faecal Management System: an In Vitro Study. WHR13107 MA106. May 8 2008. Data on file, ConvaTec. **12.** Use of Filtered Faecal Collection Bags to Contain *Clostridium difficile*: an In vitro Study. WHR13274 MA138. 25 September 2009. Data on file, ConvaTec **13.** ConvaTec US Category Market Share Report, 2009 4th Quarter. Data on file, ConvaTec.

Ordering information

Flexi-Seal™ SIGNAL™ FMS

Flexi-Seal™ SIGNAL™ FMS Kit* (1 kit/box)	418000
Flexi-Seal™ FMS Collection Bag with Charcoal Filter (10/box)	411102
Privacy™ Collection Bag with APS filter (10 Bags)	411108

* Each kit comes with 3 Flexi-Seal™ FMS Collection Bags with Charcoal Filter.

Flexi-Seal™ SIGNAL™
The seal of innovation™

TM indicates trademarks of ConvaTec Inc. Flexi-Seal, Flexi-Seal SIGNAL and the Flexi-Seal logo are registered trademarks in the United States.

© 2014 ConvaTec Inc. AP-010538-MM May 2014 CCC152

ConvaTec (Australia) Pty Limited. ABN 70 131 232 570. Unipark Monash, Building 2, Ground Floor, 195 Wellington Road, Clayton, VIC 3168 Australia. PO Box 63, Mulgrave, VIC 3170. Phone: (03) 9239 2700 Facsimile: (03) 9239 2742. Customer Support Freecall: 1800 339 412. www.convatec.com.au
ConvaTec (New Zealand) Limited. AK2135265 PO Box 62663, Greenlane 1546 New Zealand. Phone: 0800 441 763.



ConvaTec